TCG Labs-Soleil is a venture capital firm based in South San Francisco that was founded in 2023. It is a partnership between TCG Labs Fund I and Soleil, an independent R&D hub. TCG Labs-Soleil's model is a "venture capital-biotech" model that combines TCG Labs Fund I and Soleil to establish and oversee a suite of portfolio programs. TCG Labs-Soleil's integrated ecosystem helps to fund, discover, and develop single-asset biologic therapies. 

TCG Labs - Soleil

Director / Senior Director, Project Management

Director / Sr. Director of Quality Assurance - GxP

Director, CMC Project Management and Alliance Management

Scientist II / Sr. Scientist, Antibody Engineering

Scientist I, II /Sr. Scientist, In Vitro Pharmacology

Associate Director of Translational Assays


                Biotech incubated by TCG Labs inks $210M deal for EpimAb’s T-cell engager
              

Our unique "One Lab, One Team" model breaks down traditional barriers, allowing us to act swiftly, kickstart projects with high potential, and navigate past the common obstacles that hinder the development of groundbreaking drugs. Here, every member is empowered and incentivized like a scientific founder, driving them to approach each therapeutic program with the dedication and urgency of a "lead asset."  

Every TCG Labs Soleil portfolio company is built around a single, high-potential program. Our model allows for dedicated capital, focused R&D execution and clear paths to partnership.

Want to see how it works? 

Explore more: https://lnkd.in/gn5QqCkU

#Biotech 
#Partnering 
#BD

Are you headed to San Diego? TCG Labs-Soleil will be at BIO International Convention 2024 June 3-6. Let's connect and explore opportunities together. Schedule a BIO One-on-One Partnering meeting with us. Looking forward to great conversations! Learn more: https://lnkd.in/gi5_GMyh

At TCG Labs-Soleil, we're all about bringing together smart people and their brilliant ideas to make a real difference in healthcare. We form and manage independent portfolio companies, each with their own special project, guiding them from the drawing board to the real world where they can start changing lives.

We're not just about one thing; whether it's biologics, small molecules, or anything in between, we want to hear about it. Our goal? To make sure no good idea goes unnoticed. We love new ideas, whether they come from a university lab, a biotech startup, or a chat over coffee with industry friends. 

Let's make something amazing together!  https://lnkd.in/gCV9YAp5

#InnovationForHealth #BigIdeas #HealthcareHeroes #MakingADifference #JoinUs

Biotech incubated by TCG Labs inks $210M deal for EpimAb's T-cell engager - Fierce Biotech


                TCG's R&D venture team makes a T cell engager deal with Shanghai biotech
              

Juri Biosciences, a TCG Labs Soleil portfolio company, has entered into an exclusive worldwide licensing agreement with EpimAb Biotherapeutics, Inc. to develop a KLK2-targeted T-cell engager for metastatic prostate cancer.

KLK2 is a highly prostate-specific antigen with strong therapeutic potential. This agreement reflects the strength of our venture-biotech model, bringing together scientific leadership, focused capital, and operational execution to accelerate promising programs into the clinic.

We're honored to collaborate with Dr. Charles Sawyers, a pioneer in prostate cancer research, to advance this precision immunotherapy.

Read more: https://lnkd.in/g6Ez7kV8

#Biotech #ProstateCancer #TCellEngager #VentureBiotech


Couldn't make it to this year's #BIO International Convention? That's okay! We're always excited to hear from #scientific founders, innovators, and potential #partners. Reach out to Lucinda Quan and Eric Gomez anytime—and follow us to see how our portfolio companies and programs grow from innovative ideas to experimental validation. We look forward to exploring opportunities together.

TCG-backed Juri pays $210M for EpimAb’s clinic-ready prostate cancer T-cell engager - FirstWord Pharma

Hey there, scientific innovators! If you’ve been dreaming up ways to tackle serious health issues and have a novel idea, we're looking for you. With a track record of transforming big ideas into real treatments, we've got the brains and the heart to bring your vision to life.

Picture this: the energy and excitement of a startup, combined with the wisdom of experts who've been there, done that, and the kind of funding that says, "Yes, we believe in this." Sounds good? Let's make it happen.

Ready to learn more? Click here: https://lnkd.in/gCV9YAp5

#DreamTeam #HealthInnovation #StartupVibes #ChangeMakers

TCG’s R&D venture team makes a T cell engager deal with Shanghai biotech - Endpoints News

Every team member at TCG Labs Soleil is empowered and incentivized like a scientific founder. 

That’s because groundbreaking therapies require more than expertise. 

They demand ownership, dedication, and urgency.

This unique approach inspires our team to treat every therapeutic program as if it were their lead asset, channeling their passion and focus into developing solutions that matter.

With this founder-driven mindset, we’re not just advancing therapies—we’re redefining what’s possible in drug discovery and development.  https://lnkd.in/g-5SYBjK

#ScientificInnovation #Biotech #DrugDiscovery #Careers

Early 2024 saw an uptick in dealmaking activity in the bio/pharma industry, and this momentum is likely to continue. What is attractive? Acquiring de-risked, quality assets that can uplift the innovation deficit and replenish revenue streams. TCG Labs Soleil is poised to deliver. Our model offers pharma and biotech with vetted assets ready for efficient adoption and development.  Learn more: https://lnkd.in/gCV9YAp5

Epimab sells bispecific T-cell engager to Juri in $210M deal - BioWorld MedTech

We’re heading to the J.P. Morgan Healthcare Conference 2025 next week.

If you're attending, we’d love to connect. Let’s schedule time to discuss how our pipeline of de-risked, innovative single-asset therapeutics addressing some of the most critical areas of unmet medical need today is designed for seamless portfolio integration.

Drop us a message or comment below to set up a meeting. See you in San Francisco!

#JPM2025 #HealthcareInnovation #Partnerships #Biotech #Pharma  

TCG Labs Soleil is headed to Boston for #BIO25.

We’re excited to connect with #biotech innovators and community advocates from around the world to exchange ideas, share stories, and forge meaningful partnerships.

If you're attending, let’s schedule time to discuss how our pipeline of de-risked, single-asset therapeutics is tailored for seamless portfolio integration.

Send us a message or comment below to set up a meeting.  

https://lnkd.in/gn5QqCkU

#BIO2025 #Biotech #LifeSciences #Partnerships #Innovation #Healthcare

TCG Labs Soleil exclusively funds, discovers, and develops single-asset therapies that are primed for strategic transactions.

Here’s how it works:

Focused Single-Asset Programs: Streamlined for speed, efficiency, and reduced risk in drug development.

Vetted Assets: Each program is meticulously designed to accelerate the path from idea to human proof of concept.

Strategic Fit: Ideal for organizations seeking a faster, smarter approach to delivering novel therapies to patients.

Whether you're looking to expedite development timelines or enhance your portfolio with high-potential assets, our model offers a catered solution.

#DrugDevelopment #Innovation #Biotech #StrategicPartnerships

Biotech dealmaking in today’s environment is not without obstacles. Rising interest rates, regulatory pressures, and aggressive drug pricing policies could temper the M&A momentum. For small biotechs, the message is clear: capital efficiency and a focused pipeline are key to staying competitive in a buyer’s market.

At the same time, large pharma companies are sitting on deployable capital, looking for strategic assets in high-value areas like obesity, oncology, and rare diseases. But with R&D costs rising, the way we discover and develop drugs needs to evolve.

The future belongs to lean, focused, and strategically positioned programs that can seamlessly integrate into larger portfolios. 

At TCG Labs Soleil, we streamline drug discovery with a single-asset, capital-efficient model, ensuring that each program is primed for strategic transactions. In a shifting dealmaking environment, we believe adaptability and precision will define the winners.

#DrugDiscovery #StrategicPartnerships #Biotech #DrugDiscovery #LifeSciences

Juri Biosciences, a TCG Labs Soleil Portfolio Company, and - GlobeNewswire

KBR Awarded $476M Base Operations Support Contract in Djibouti - The Manila Times

 TCG's R&D venture team makes a T cell engager deal with Shanghai biotech 

Imagine having a transformative concept for a therapy that could address serious diseases, but lacking the operational infrastructure and resources to bring it to life.

At TCG Labs Soleil, we bridge the gap between ideas and tangible solutions.

Here’s how we can help:

✅ Present your promising idea to us.
✅ Access dedicated capital and collaborate with our seasoned drug discovery team to transform your vision into a human proof of concept.
✅ Establish an independent portfolio company around your asset, supported by elite scientific and operational expertise.
✅ Experience a streamlined development process designed for rapid progress, while preserving your undiluted ownership stake.

Together, we can turn your innovative ideas into therapies for patients facing serious diseases.

Are you ready to take the next step? Let’s build something extraordinary together.  https://lnkd.in/gCV9YAp5

#DrugDiscovery #Innovation #Biotech #ScientificFounders

At TCG Labs-Soleil, we're pioneering a new era of drug discovery, offering unique advantages to scientific founders, drug hunters, and the pharma and biotech industries. Our model is designed to streamline the journey from idea to clinical application. This includes:

🚀 Efficient R&D: Scientific founders gain access to a top-tier drug discovery team and dedicated funding, ensuring a smooth transition from concept to reality.

🎯 Focused Approach: We form portfolio companies around single-asset programs, emphasizing efficient development and clinical validation.  

🤝Simple Transactions: Our model supports flexible, strategic partnerships, each grounded in human proof of concept and ready for seamless integration into late-stage development efforts.

🔬 One Lab, One Team: Our evergreen team model ensures continuity, focus, and productivity, allowing us to excel in what we do best – innovating for the future of healthcare.

Discover how TCG Labs-Soleil can revolutionize your drug development pipeline. Learn more: https://lnkd.in/gzspeSsd 

#PharmaPartnerships #Founders #BiotechInnovation #TCGLabsSoleil #DrugDiscovery

 Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer 

Exclusive: Column Group raises a new $400M+ fund and R&D hub for single-asset biologics companies - Endpoints News

It’s been an incredible #JPMWeek, filled with great meetings and an impressive turnout from across the #biotech and #pharma ecosystem. As we reflect on the conversations and connections from this week, we’re excited about the momentum behind our partnering strategy. By focusing on single-asset programs across multiple therapeutic areas, with a variety of modalities, we offer pharma and biotech companies with attractive opportunities for strategic transactions that accelerate innovation and deliver impactful therapies to patients.

Learn more about our approach or explore potential collaboration: https://lnkd.in/gn5QqCkU 

Looking forward to continuing these conversations in the weeks ahead!

TCG Labs Soleil is building a suite of home-grown portfolio companies, each individually focusing on single-asset programs spanning #autoimmune diseases to #oncology.  

Curious? 

Let’s connect. 

#biotech #pharma #partnering 

Did you know? 

TCG Labs Soleil’s fully integrated R&D and investment model provides distinct advantages:

1️⃣ For biopharma partners – Access to de-risked, high-value assets optimized for seamless integration into late-stage pipelines.

2️⃣ For scientific founders, academic institutions, and early-stage innovators – Capital, deep scientific expertise, and operational support, leveraging Soleil’s drug discovery team and TCG Labs’ exclusive venture fund to efficiently advance early discoveries without the need to build a standalone company.

How a VC and a biotech founder plan to create a new biotech model - San Francisco Business Times - The Business Journals

Meet Dr. Josh Lichtman, Chief Science Officer and Co-Founder of TCG Labs Soleil. Josh leads our top-notch R&D hub, guiding a stellar scientific team dedicated to efficient drug development that result in innovative single-asset programs. Learn more about Josh: https://lnkd.in/gXN2vEJb
#MeetOurTeam #InnovationInScience  

Meet Jin-Long Chen , CEO of TCG Labs-Soleil.  A drug discovery expert at his core, he has successfully guided programs from the earliest stages to developing multiple new medicines that have positively impacted #patient care. Read more: https://lnkd.in/gBm_Ej49

TCG Labs - Soleil

About: